(Q38109245)

29 August 2017

Safety of neurokinin-1 receptor antagonists (English)

1 reference

29 August 2017

Miguel Muñoz

1

1 reference

PubMed ID

23706125

29 August 2017

Rafael Coveñas

series ordinal

2

1 reference

PubMed ID

23706125

29 August 2017

language of work or name

English

0 references

publication date

25 May 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

1 reference

29 August 2017

12

1 reference

29 August 2017

5

1 reference

29 August 2017

673-685

1 reference

NK-1 receptor antagonists: a new paradigm in pharmacological therapy

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Targeting opioid and neurokinin-1 receptors to treat alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant: a review of its use in the prevention of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.804059

10.1517/14740338.2013.804059

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23706125